Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | PDE6D | O43924 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30534775 | 1.00 | PTGS2 (0.48) | PTGS2LTA4HL3MBTL1KMT2AALDH1A1 | |
| Indole SCHEMBL8436345 | 0.89 | ESR1 (0.42) | PTGS2LTA4HL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL5075270 | 0.83 | PTGS2 (0.53) | PTGS2L3MBTL1KMT2AALDH1A1TAAR1 | |
| SCHEMBL4887683 | 0.81 | L3MBTL1 (0.61) | PTGS2L3MBTL1KMT2AALDH1A1ESR1 | |
| SCHEMBL7799991 | 0.80 | L3MBTL1 (0.46) | PTGS2L3MBTL1KMT2AALDH1A1BACE1 | |
| SCHEMBL6535399 | 0.79 | HRH3 (0.59) | LTA4HESR1HRH3 | |
| SCHEMBL6086162 | 0.78 | PTGS2 (0.71) | PTGS2L3MBTL1KMT2AALDH1A1ESR1 | |
| SCHEMBL2823906 | 0.77 | L3MBTL1 (0.57) | PTGS2L3MBTL1KMT2AALDH1A1ESR1 | |
| SCHEMBL2828465 | 0.76 | FFAR1 (0.61) | L3MBTL1ALDH1A1NR1H2 | |
| SCHEMBL27540149 | 0.75 | HTR1B (0.44) | KMT2AALDH1A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| EP-4376848-A1 | 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA (GEDATOLISIB) AND ITS COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | Celcuity Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| CN-108348605-B | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| WO-2023009438-A1 | 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA (GEDATOLISIB) AND ITS COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | CELCUITY INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230022525-A1 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-26 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-6005102-A | NOVEL INTERMEDIATES WHICH MAY BE USED IN THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS FOR ANTI-ESTROGENIC AND MATRIX METALLOPROTEINASES-INHIBITING UTILITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999059581-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999059581-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| CN-1170719-A | Estrogenic agents | AMERICAN HOME PROD (US) | 1998-01-21 | — | — | CN | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022525-A1 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | CDK4, CDKN1A, CDK2 | PTGS2 2176/4885LTA4H 2710/4885L3MBTL1 2173/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | PTGS2 1793/4885LTA4H 4081/4885L3MBTL1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.